Michael A. Perricone
Research Subjects
Research Interests
Michael A. Perricone has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Johanne M. Kaplan
Genzyme Corporation, P.O. Box 9322, Framingham, MA 01701, USA
4 shared publicationsKaren A. Smith
Genzyme Corporation, P.O. Box 9322, Framingham, MA 01701, USA
4 shared publicationsBruce L. Roberts
2 shared publicationsJudith A. St. George
2 shared publicationsKirsten A. Claussen
2 shared publicationsCarol R. Sacks
Genzyme, Framingham, MA 01701
1 shared publication
Latest Publications
- Open Access
- 22 October 2008
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 6 (1) , 61
Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients
HLA-A2 tetramer flow cytometry, IFNγ real time RT-PCR and IFNγ ELISPOT assays are commonly used as surrogate immunological endpoints for cancer immunotherapy. While these are often used as research assays to assess patient's immunologic response, assay validation is necessary to ensure reliable and reproducible results and enable more accurate data interpretation. Here we describe a rigorous validation approach for each of these assays prior to their use for clinical sample analysis.
- 22 October 2008
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 6 (1) , 61
Open AccessValidation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients
HLA-A2 tetramer flow cytometry, IFNγ real time RT-PCR and IFNγ ELISPOT assays are commonly used as surrogate immunological endpoints for cancer immunotherapy. While these are often used as research assays to assess patient's immunologic response, assay validation is necessary to ensure reliable and reproducible results and enable more accurate data interpretation. Here we describe a rigorous validation approach for each of these assays prior to their use for clinical sample analysis.
- 20 April 2008
- Published by Elsevier in Journal of Immunological Methods
- Vol. 333 (1-2) , 51-60
Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies
- 20 April 2008
- Published by Elsevier in Journal of Immunological Methods
- Vol. 333 (1-2) , 51-60
Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies
- 1 January 2004
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 27 (4) , 273-281
Enhanced Efficacy of Melanoma Vaccines in the Absence of B Lymphocytes
Provoking a specific cellular immune response against tumor-associated antigens is a promising therapeutic strategy to treat cancers with defined antigens such as melanoma. In recent clinical trials, however, immune responses against melanoma antigens have been elicited without consistent clinical responses, suggesting the need for approaches that potentiate the specific cellular immune response. Since B lymphocytes have been reported to exert a negative effect on the cellular arm of the immune response in certain model systems, the authors compared the protective immunity elicited by melanoma antigens in B cell-deficient μMT mice to that obtained in fully immunocompetent C57BL/6 mice. Immunization with melanoma-associated antigens was accomplished using recombinant adenovirus (Ad) vectors encoding human gp100 (Ad2/gp100) or murine TRP-2 (Ad2/mTRP-2). A single dose of Ad2/gp100 or Ad2/mTRP-2 inhibited the growth of established subcutaneous B16 melanoma tumors in B cell-deficient but not wild-type C57BL/6 mice. The enhanced tumor protection observed in B cell-deficient mice appeared to be associated with potentiation of the magnitude and longevity of the specific cellular immune response. Natural killer (NK) cells were also found to be essential to the protective immune response in μMT mice because NK cell depletion with anti-asialo-GM1 antibody resulted in both the loss of tumor growth suppression and attenuation of the specific cellular immune response. The authors conclude that the protective cell-mediated immunity provoked by Ad-based cancer vaccines is enhanced in the absence of B cells, suggesting that a therapeutic regimen that includes depletion of B lymphocytes may be beneficial to cancer vaccine therapy.
- 1 January 2004
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 27 (4) , 273-281
Enhanced Efficacy of Melanoma Vaccines in the Absence of B Lymphocytes
Provoking a specific cellular immune response against tumor-associated antigens is a promising therapeutic strategy to treat cancers with defined antigens such as melanoma. In recent clinical trials, however, immune responses against melanoma antigens have been elicited without consistent clinical responses, suggesting the need for approaches that potentiate the specific cellular immune response. Since B lymphocytes have been reported to exert a negative effect on the cellular arm of the immune response in certain model systems, the authors compared the protective immunity elicited by melanoma antigens in B cell-deficient μMT mice to that obtained in fully immunocompetent C57BL/6 mice. Immunization with melanoma-associated antigens was accomplished using recombinant adenovirus (Ad) vectors encoding human gp100 (Ad2/gp100) or murine TRP-2 (Ad2/mTRP-2). A single dose of Ad2/gp100 or Ad2/mTRP-2 inhibited the growth of established subcutaneous B16 melanoma tumors in B cell-deficient but not wild-type C57BL/6 mice. The enhanced tumor protection observed in B cell-deficient mice appeared to be associated with potentiation of the magnitude and longevity of the specific cellular immune response. Natural killer (NK) cells were also found to be essential to the protective immune response in μMT mice because NK cell depletion with anti-asialo-GM1 antibody resulted in both the loss of tumor growth suppression and attenuation of the specific cellular immune response. The authors conclude that the protective cell-mediated immunity provoked by Ad-based cancer vaccines is enhanced in the absence of B cells, suggesting that a therapeutic regimen that includes depletion of B lymphocytes may be beneficial to cancer vaccine therapy.
- 27 November 2001
- Published by Elsevier in Journal of Immunological Methods
- Vol. 259 (1-2) , 129-138
Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR
- 27 November 2001
- Published by Elsevier in Journal of Immunological Methods
- Vol. 259 (1-2) , 129-138
Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR
- 20 September 2000
- Published by SAGE Publications in Human Gene Therapy
- Vol. 11 (14) , 1997-2008
Inhibitory Effect of Cystic Fibrosis Sputum on AdenovirusMediated Gene Transfer in Cultured Epithelial Cells
Effective gene transfer to the airway epithelial cells of individuals with cystic fibrosis (CF) requires gene therapy vectors to effectively penetrate the mucous lining of the airways of these patients. In this study, we examined the effects of the aqueous sol fraction of sputum recovered from CF patients (CF sol) on adenovirus (Ad)-mediated gene transfer to cultured epithelial cells. Sputum collected from patients with CF was separated into aqueous sol and gel fractions by ultracentrifugation and the sol fraction from different individuals was pooled. To determine if CF sol affects Ad-mediated transfection, Fisher rat thyroid (FRT) epithelial cells or normal human bronchial epithelial (NHBE) cells were infected with an Ad encoding β-galactosidase (Ad2/βgal-2) in the presence or absence of the pooled CF sol. Transfection efficiency was determined by measuring β-Gal activity. CF sol significantly inhibited Ad2-mediated gene transfer in a dose-dependent manner when the vector was incubated with CF sol prior to exposure to the cells. In contrast, preincubation of the cells with the sol was without effect. The inhibition of Ad-mediated gene transfer by CF sol was not related to its low pH, was abrogated by preadsorption with an Ad2 serotype vector, and was neutralized by heat treatment, but was not affected by treatment with protease inhibitors. Analysis of CF sol fractions from seven different individuals with CF showed inhibition of Ad-mediated gene transfer in four of the seven samples tested and, further, the inhibitory effect was correlated with the presence of Ad-specific antibodies. We conclude that preexisting adenovirus-specific antibodies present in some of the patient samples were the predominant factor inhibiting Ad-mediated gene transfer.
- 20 September 2000
- Published by SAGE Publications in Human Gene Therapy
- Vol. 11 (14) , 1997-2008
Inhibitory Effect of Cystic Fibrosis Sputum on AdenovirusMediated Gene Transfer in Cultured Epithelial Cells
Effective gene transfer to the airway epithelial cells of individuals with cystic fibrosis (CF) requires gene therapy vectors to effectively penetrate the mucous lining of the airways of these patients. In this study, we examined the effects of the aqueous sol fraction of sputum recovered from CF patients (CF sol) on adenovirus (Ad)-mediated gene transfer to cultured epithelial cells. Sputum collected from patients with CF was separated into aqueous sol and gel fractions by ultracentrifugation and the sol fraction from different individuals was pooled. To determine if CF sol affects Ad-mediated transfection, Fisher rat thyroid (FRT) epithelial cells or normal human bronchial epithelial (NHBE) cells were infected with an Ad encoding β-galactosidase (Ad2/βgal-2) in the presence or absence of the pooled CF sol. Transfection efficiency was determined by measuring β-Gal activity. CF sol significantly inhibited Ad2-mediated gene transfer in a dose-dependent manner when the vector was incubated with CF sol prior to exposure to the cells. In contrast, preincubation of the cells with the sol was without effect. The inhibition of Ad-mediated gene transfer by CF sol was not related to its low pH, was abrogated by preadsorption with an Ad2 serotype vector, and was neutralized by heat treatment, but was not affected by treatment with protease inhibitors. Analysis of CF sol fractions from seven different individuals with CF showed inhibition of Ad-mediated gene transfer in four of the seven samples tested and, further, the inhibitory effect was correlated with the presence of Ad-specific antibodies. We conclude that preexisting adenovirus-specific antibodies present in some of the patient samples were the predominant factor inhibiting Ad-mediated gene transfer.
- Open Access
- 31 March 2000
- Published by Elsevier in Molecular Therapy
- Vol. 1 (3) , 275-284
Immunogene Therapy for Murine Melanoma Using Recombinant Adenoviral Vectors Expressing Melanoma-Associated Antigens
- 31 March 2000
- Published by Elsevier in Molecular Therapy
- Vol. 1 (3) , 275-284
Open AccessImmunogene Therapy for Murine Melanoma Using Recombinant Adenoviral Vectors Expressing Melanoma-Associated Antigens